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Purpose: This study was performed in order to evaluate the incidence and character-
istics of cytomegalovirus (CMV) infection in children with acute leukemia accord-
ing to donor source and graft type. Materials and Methods: We retrospectively 
identified children with acute leukemia who had received allogeneic hematopoietic 
cell transplantation at Samsung Medical Center in Korea from October 1998 to 
December 2009. Results: In total, 134 recipients were identified. The patients 
were classified into the following three groups: unrelated cord blood (CB, n=36), 
related bone marrow or peripheral blood stem cells (RD, n=41), and unrelated 
bone marrow or peripheral blood stem cells (UD, n=57). The 365-day cumulative 
incidence of CMV antigenemia was not significantly different among the three 
groups (CB 67% vs. RD 49% vs. UD 65%, p=0.17). However, CB recipients had 
the highest median value of peak antigenemia (CB 160/2×105 leukocytes vs. RD 
7/2×105 leukocytes vs. UD 19/2×105 leukocytes, p<0.01) and the longest duration 
of CMV antigenemia than the other stem cell source recipients (CB 87 days vs. 
RD 17 days vs. UD 28 days, p<0.01). In addition, the 730-day cumulative inci-
dence of CMV disease was the highest in the CB recipients (CB 36% vs. RD 2% 
vs. UD 5%, p<0.01). Thirteen CB recipients developed CMV disease, in which 
five of them had more than one organ involvement. Two patients, who were CB 
recipients, died of CMV pneumonia. Conclusion: This study suggests that CB re-
cipients had both longer and higher cumulative incidences of CMV infection. 
Therefore, a more aggressive and effective strategy of CMV management should 
be considered in CB recipients.
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INTRODUCTION
Cytomegalovirus (CMV) infection and disease are important causes of morbidity 
and mortality among hematopoietic cell transplantation (HCT) recipients.1-4 Among 
HCT recipients, CMV causes end organ diseases including pneumonia, gastroen-
teritis, retinitis, and hepatitis. Since the introduction of prophylactic or preemptive 
therapy against CMV, the incidence of CMV disease has been successfully re-
duced. However, CMV disease remains one of the major infectious complications Eun Sang Yi and Yae-Jean Kim
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age, sex, primary disease, type of stem cell graft, donor 
source, CMV serostatus of the donor and recipient, condi-
tioning regimen, GVHD prophylaxis, antiviral prophylaxis, 
the use of anti-thymocyte globulin (ATG), and the presence 
of GVHD. All included recipients were sorted into the fol-
lowing three groups according to donor source and graft 
type: CB, related bone marrow or peripheral blood (PB) 
stem cell (RD), and unrelated bone marrow or peripheral 
blood stem cell (UD). 
Definitions of CMV infection and disease
CMV infection was defined as isolation of CMV or detec-
tion of viral proteins or nucleic acid in any body fluid or tis-
sue specimen.20 CMV antigenemia was defined as greater 
than or equal to 1 CMV pp65 positive cell per 2×105 leuko-
cytes. CMV disease was diagnosed by signs or symptoms 
and demonstration of CMV infection (upon culture, histo-
pathologic confirmation, immunohistochemical analysis, or 
in situ hybridization) in organ biopsy specimens. In addition, 
CMV pneumonitis was diagnosed by interstitial pneumoni-
tis accompanied by CMV antigenemia, unless other patho-
gens were confirmed. CMV retinitis was diagnosed by typi-
cal lesions confirmed by an ophthalmologist. CMV central 
nervous system (CNS) disease was defined by the identifica-
tion of CNS symptoms together with the detection of CMV 
in cerebrospinal fluid samples upon a culture or polymerase 
chain reaction (PCR).
Recurrent CMV infection was defined as the develop-
ment of a new positive CMV test occurring after a 50-day 
interval free of CMV infection. The duration of CMV anti-
genemia was defined as the number of days from the first 
detection to the last detection of CMV antigenemia. The to-
tal duration of CMV antigenemia was the sum of the dura-
tion of all episodes, when recurrent infections occurred.
Management of CMV
Prior to conditioning, CMV serology of the recipient and 
donor was assessed. CMV immunoglobulin G (IgG) was 
checked by enzyme linked fluorescent assay. The test was 
considered positive when CMV IgG antibody level was   
greater than or equal to 4 AU/mL. The CMV serostatus of 
cord blood was considered as being negative.21 A CMV 
pp65 antigenemia test using immunofluorescence stain was 
performed one to three times weekly after peripheral white 
blood cell (WBC) count reached greater than or equal to 
1.0×109/L. The results of this test were presented as the num-
ber of positive cells per 2×105 leukocytes.
after HCT.5 Many factors are associated with the risk of 
CMV infection and disease. In allogeneic HCT recipients, 
the serologic status of the donor and recipient was shown to 
be the most important risk factor for CMV disease.6 Other 
risk factors for CMV infection include T-cell depletion, 
acute and chronic graft-versus-host disease (GVHD), the 
use of mismatched or unrelated donors, and the use of high 
dose corticosteroid.7-13
Cord blood transplantation (CBT) has become an increas-
ingly utilized method of HCT.14 Cord blood T cells are im-
munologically naive; therefore, they do not supply passive 
immunity to the HCT recipient. Although HCT recipients of 
all donor sources were affected by CMV antigenemia and 
disease, an increased risk for viral infections after CBT is a 
concern.4,15,16 Takami, et al.17 reported CBT itself may be cor-
related with a high incidence of CMV reactivation.  Con-
versely, Walker, et al.12 reported that cord blood (CB) recipi-
ents had similar risks of CMV infection, responses to antiviral 
therapy, and survival following CMV infection as recipients 
of either bone marrow (BM) or peripheral blood stem cells. 
Two other studies reported that stem cell source had no effect 
on CMV infection and disease.18,19 However, only a few 
studies have examined these relationship between CMV in-
fection and donor source or graft type in pediatric recipi-
ents.19 Our study was performed to study this relationship at a 
single institution with a large pediatric patient population 
managed consistently by the same physicians.
This study was performed in order to evaluate the inci-
dence and characteristics of CMV infection and disease in 
children with acute leukemia according to donor source and 
graft type.
MATERIALS AND METHODS
　　　
Study patients and characteristics
A retrospective chart review was performed in children with 
acute leukemia who received allogeneic HCT at Samsung 
Medical Center in Korea from October 1998 to December 
2009. We excluded recipients who underwent HCT twice or 
more or who received two or more stem cell sources. In to-
tal, 134 patients were included in the analysis. All patients 
underwent a myeloablative conditioning regimen. Condi-
tioning regimens were chosen depending on underlying dis-
eases, and these were maintained consistently throughout 
the study period. We identified Samsung Medical Informa-
tion System’s clinical data which included information on CMV Infection according to Cell Source in Children
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and types of grafts using the Chi-square test and Fisher’s ex-
act test with a permutation method for multiple testing of cat-
egorical data. Continuous variables were compared using the 
Kruskal-Wallis test along with a Tukey test using ranks. The 
cumulative incidences of CMV antigenemia (for 365 days) 
and disease (for 730 days) were evaluated using a Fine-Gray 
regression model.24,25 All statistical analyses were performed 
using SAS software version 9.1.3 (SAS Institute Inc., Cary, 
NC, USA) and Stata software version 11.0 (StataCorp LP, 
4905 Lakeway Drive, College Station, TX, USA).
 
RESULTS
 
Characteristics of patients
The characteristics of the patients are shown in Table 1. All 
included recipients were classified into three groups: CB 
(n=36), RD (n=41), and UD (n=57). These groups were 
similar with respect to sex, age at HCT, primary disease, and 
conditioning regimen. The median age of the recipients was 
8.2 years. The male to female ratio was 1.6 : 1. ATG was 
used most frequently in CB (34/36) than the other two 
groups (p<0.01). The proportion of positive CMV serology 
recipients was high in all three groups (CB 91.7%, RD 
97.5%, UD 96.5%). In addition, the proportion of positive 
CMV serology donors was high (RD 73.1%, UD 87.7%). 
All recipients, except for one in the RD group, received only 
CsA as GVHD prophylaxis, whereas patients in the other 
groups received CsA plus another immunosuppressant 
(p<0.01). One of the UD recipients received tacrolimus. 
Acyclovir was used as herpes virus prophylaxis in all groups. 
Seven patients in the UD group received ganciclovir in addi-
tion to acyclovir. Fewer patients developed grade II to IV 
acute GVHD in the RD group than other patients (p=0.01). 
Extensive chronic GVHD occurred similarly among the 
groups (p=0.53).
Cumulative incidence and clinical features of CMV 
disease
The 365-day cumulative incidence of CMV antigenemia is 
shown in Fig. 1. The clinical features of CMV antigenemia 
are shown in Table 2. The cumulative incidence of CMV an-
tigenemia was 67% in CB, 49% in RD, and 65% in the UD 
group. There was no significant differences among these 
groups in cumulative incidence of CMV antigenemia. First, 
CMV antigenemia was detected earlier in CB recipients 
(p=0.05). CB recipients also had the highest median value of 
Acyclovir was given as a herpes virus prophylactic drug 
for 4 weeks from the day before transplantation (5 mg/kg/
dose q 8 hrs). For CMV prophylaxis, from the 2001 to 2002 
period, ganciclovir was used in certain high risk recipients 
of unrelated donor grafts, but this ganciclovir-based pro-
phylaxis for CMV infection was not used thereafter. Strate-
gies for pre-emptive therapy were maintained throughout 
the study period, using antigenemia as a surrogate marker 
for CMV viremia. If CMV antigenemia was detected with-
out evidence of CMV disease, preemptive first-line therapy 
was started with an induction dose of intravenous ganciclo-
vir (5 mg/kg twice daily i.v.). In patients with a stable con-
dition after post transplant day +30, antiviral therapy was 
started only when CMV antigenemia was detected above 
5/2×105 leukocytes or with increasing CMV antigenemia 
during follow-up. Foscarnet (180 mg/kg/day i.v. in divided 
doses) was used in patients with severe neutropenia in place 
of ganciclovir. A second-line treatment with intravenous 
foscarnet was generally started in recipients with prolonged 
CMV antigenemia. Cidofovir or CMV hyperimmunoglob-
ulin was also used for patients who appeared to fail previ-
ous treatments. Tests for CMV antiviral resistance muta-
tions were not available.
All packed red blood cells and platelets were transfused 
using leukocyte-depleting filters and radiation. Granulo-
cyte-colony stimulating factor was given to maintain abso-
lute neutrophil count above 1.0×109/L and total WBC count 
above 2.0×109/L.
GVHD prophylaxis
GVHD prophylaxis consisted mainly of cyclosporine A 
(CsA) alone or CsA with other immunosuppressants (myco-
phenolate, steroid, methotrexate). Protocols for GVHD pro-
phylaxis was consistently maintained, except for CB recipi-
ents. CB recipients received CsA and methylprednisolone 
until December 2004 and received CsA+mycophenolate be-
ginning in January 2005. Most RD recipients and UD recipi-
ents received CsA only or CsA+methotrexate, respectively, 
as the GVHD prophylaxis throughout the study period. 
Diagnosis of acute and chronic GVHD was based on stan-
dard clinical criteria and biopsy when available.22,23 Treat-
ment of acute GVHD stage II or greater began with steroids, 
usually methylprednisolone. 
Statistics
Patient characteristics, GVHD, and clinical features of CMV 
infection and disease were compared across donor sources Eun Sang Yi and Yae-Jean Kim
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Table 1. Characteristics of the Patients
CB (n=36) RD (n=41) UD (n=57) p value
Sex       0.91
    Male    23 (63.9%)    25 (61.0%) 34 (59.7%)
    Female    13 (36.1%)    16 (39.0%) 23 (40.4%)
Median age, yrs (range)      8.9 (0.6-18.5)      8.2 (2.2-16.0)   7.4 (0.4-19.8)   0.72
Primary disease   0.96
    ALL/ABL    19 (52.8%)    23 (56.1%) 31 (54.4%)
    AML    17 (47.2%)    18 (43.9%) 26 (45.6%)
Stem cell source <0.01
   BM    15 (36.6%) 43 (75.4%)
   PBSC    26 (63.4%) 14 (24.6%)
   CB   36 (100%)
Conditioning regimen   0.72
    TBI-based    12 (33.3%)    16 (39.0%) 25 (43.9%)
    Busulfan-based    23 (63.9%)    22 (53.7%) 30 (52.6%)
    Others    1 (2.8%)    3 (7.3%) 2 (3.5%)
ATG    34 (94.4%) 0 (0%)   7 (12.3%) <0.01
CMV serostatus <0.01
    R-/D-    3 (8.3%)
    R-/D+    1 (2.4%) 2 (3.5%)
    R+/D-    33 (91.7%)    11 (26.8%)   7 (12.3%)
    R+/D+    29 (70.7%) 48 (84.2%)
GVHD prophylaxis <0.01
    CsA    43 (97.7%) 2 (3.2%)
    CsA+others   38 (100%)    1 (2.3%) 60 (95.2%) 
    Others 1 (1.6%)
CMV prophylaxis with GCV 0 (0%)  0 (0%)   7 (12.3%) <0.01
Grade II-IV acute GVHD    14 (38.9%)      8 (19.5%) 28 (49.1%)   0.01
Extensive chronic GVHD      7 (19.4%)    10 (24.4%)   9 (15.8%)   0.57
CB, cord blood; RD, related bone marrow or peripheral blood stem cell donor; UD, unrelated bone marrow or peripheral blood stem cell donor; ALL, acute 
lymphocytic leukemia; ABL, acute biphenotypic leukemia; AML, acute myeloid leukemia; BM, bone marrow; PBSC, peripheral blood stem cell; TBI, total 
body irradiation; ATG, anti-thymocyte globulin; R, recipient; D, donor; GVHD, graft-versus-host disease; CsA, cyclosporine A; GCV, ganciclovir; CMV, cyto-
megalovirus; TBI, total body irradiation.
Values are presented as the number of patients (%) if there are no comments.
TBI was given at a dose of 333 cGY per day for 3 days.
Fig. 1. Cumulative incidence of CMV antigenemia. CB, cord blood; UD, un-
related bone marrow or peripheral blood stem cell donor; RD, related bone 
marrow or peripheral blood stem cell donor; CMV, cytomegalovirus.
Fig. 2. Cumulative incidence of CMV disease. CB, cord blood; UD, unrelated 
bone marrow or peripheral blood stem cell donor; RD, related bone mar-
row or peripheral blood stem cell donor; CMV, cytomegalovirus.
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for acute myeloid leukemia. He received multiple immuno-
suppressive agents to control chronic GVHD. He developed 
CMV reactivation after the use of alemtuzumab, which even-
tually progressed to CMV pneumonitis and was not con-
trolled despite aggressive antiviral treatment. The other pa-
tient was a 10-month old infant who received CBT for 
infantile acute lymphocytic leukemia (ALL). He received 
steroid for GVHD and developed CMV antigenemia at day 
+28. CMV disease (pneumonitis, retinitis, and CNS disease) 
was uncontrollable despite treatment. One patient in the RD 
group developed organ involvement, which was CMV coli-
tis. This patient was a 16 year old male with ALL who re-
ceived a sibling matched allogeneic bone marrow transplan-
tation. He developed chronic GVHD, which required 
immunosuppressants including cyclosporine, azathioprine, 
and mycophenolate. He developed hematochezia for which a 
colonoscopy was performed and pathologic confirmation 
was made for CMV colitis. The patient received ganciclovir; 
however, the general condition was very poor presenting 
multiple other complications, and he died.
DISCUSSION
Serious CMV infection can complicate the post-transplant 
peak CMV antigenemia (CB 160/2×105 leukocytes vs. RD 
7/2×105 leukocytes vs. UD 19/2×105 leukocytes, p<0.01). In 
addition, the duration of CMV antigenemia was the longest 
in the CB group (CB 87 days vs. RD 17 days vs. UD 28 
days, p<0.01). However, the recurrence of CMV antigen-
emia occurred similarly among all three groups (p=0.77).
The 730-day cumulative incidence of CMV disease is 
shown in Fig. 2. The clinical features of CMV disease are 
shown in Table 3. CB recipients had the highest cumulative 
incidence of CMV disease (CB 36% vs. RD 2% vs. UD 5%, 
p<0.01). All of the recipients with CMV disease had CMV 
antigenemia before the diagnosis of organ involvement. 
Among all of the groups, 17 patients developed CMV dis-
ease at 24 organ sites (colitis in 9 patients, retinitis in 7 pa-
tients, pneumonia in 5 patients, CNS disease in 2 patients, 
and hepatitis in 1 patient). While HCT recipients in the RD 
and UD groups had only one organ involvement during 
CMV disease, five of the 13 CB recipients (38.5%) devel-
oped multi-organ CMV disease. Three patients had pneumo-
nia plus retinitis. Of which, two patients had three-organ in-
volvements; one patient had retinitis, colitis, and CNS 
disease; and the other had pneumonia, retinitis, and CNS dis-
ease. Among the 17 patients with CMV disease, two patients 
died of interstitial CMV pneumonitis. Both of them were CB 
recipients. One was a 12-year old male who received CBT 
Table 2. Clinical Features of CMV Antigenemia
CB (n=36) RD (n=41) UD (n=57) p value
Number of patients 24/36 (67%) 20/41 (49%) 37/57 (65%)   0.18
Median day of first detection (range)         25 (13-68)           27 (14-365)           30 (14-104)   0.05
Median number of peak level (range)         160 (1-2120)           7 (1-134)         19 (1-351) <0.01
Median duration (range)         87 (0-780)         17 (0-218)         28 (0-347) <0.01
Recurrence            4 (16.7%)            4 (20.0%)            9 (24.3%)    0.77
CB, cord blood; RD, related bone marrow or peripheral blood stem cell donor; UD, unrelated bone marrow or peripheral blood stem cell donor; CMV, cyto-
megalovirus.
Values are presented as the number of patients (%) if there are no comments.
Table 3. Clinical Features of CMV Disease
CB (n=36) RD (n=41) UD (n=57) Total
Number of patients (%)    13/36 (36)  1/41 (2) 3/57 (5) 17
Site of disease 20 1 3 24
    Colitis   6 1 2 9
    Retinitis   6 1 7
    Pneumonia   5 5
    CNS disease    2 2
    Hepatitis   1 1
Median day of diagnosis (range) 54 (35-718) 460 120 (94-140) p=0.11
Death due to CMV   2
CB, cord blood; RD, related bone marrow or peripheral blood stem cell donor; UD, unrelated bone marrow or peripheral blood stem cell donor; CMV, cyto-
megalovirus; CNS, central nervous system.
Values are presented as the number of case if there are no comments.Eun Sang Yi and Yae-Jean Kim
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CMV reactivation is controlled by CMV-specific T cells.37,38 
ATG possibly damaged recipient-derived anti-CMV im-
mune cells, which may have been important because CB re-
cipients can not gain anti-CMV immunity from the donor 
stem cells.
Improvement of diagnostic methods and antiviral agents 
has enabled early detection of CMV to prevent reactivation 
and subsequent development of CMV diseases. Recent 
guidelines recommend antiviral prophylaxis with CMV reac-
tivation screening or empiric treatment.31 When prophylaxis 
is chosen against CMV infection, chemoprophylaxis is rec-
ommended from the engraftment until at least day +100 after 
HCT. Otherwise, all allogeneic recipients including CB re-
cipients should receive preemptive treatment when any level 
of CMV PCR or antigenemia was detected during less than 
100 days post-HCT. In our institution, acyclovir prophylaxis 
was given until day +28 for herpes virus infection and pre-
emptive treatment was given later, when CMV antigenemia 
was detected during follow-up. All of our CB recipients de-
veloped CMV infection before day +100 post-HCT.
There are many reports being published in the field of 
transplant-related CMV infection. Our study is limited in 
that the data were collected retrospectively from a single 
center that included only pediatric patients with leukemia. 
However, we tried to select only patients with leukemia to 
reduce the heterogeneity among patients.  
In conclusion, in pediatric patients with acute leukemia 
who received allogeneic HCT, CBT was associated with in-
creased risk of prolonged CMV antigenemia, higher viral 
loads, and more serious CMV diseases compared to unre-
lated or related PB or BM allogeneic HCT recipients. 
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